Velesco Opens cGMP Production Facility and Moves to Expanded Lab Space
(Plymouth, MI; June 9, 2009) –
Velesco Pharmaceutical Services
, a company providing analytical method development, drug formulation, stability testing and consulting services to biotech and pharmaceutical companies, opened a manufacturing facility and office in Kalamazoo, MI and has moved its Ann Arbor, MI laboratories to the Michigan Life Science and Innovation Center (MLSIC) in Plymouth, MI.
Velesco’s new 10,000 square foot office and manufacturing facility at the Kalamazoo Commerce Center will manufacture non-sterile cGMP clinical trial supplies for pharmaceutical companies developing new medicines. This facility will focus on providing clinical supplies for early phase trials. Product offerings include powder-in-capsule, powder-in-bottle, ointments/creams, oral and topical liquids, over-encapsulation for blinded studies and packaging.
The company move provides expanded space to accommodate the growth of its analytical and drug formulation laboratory services.
“Velesco’s addition of clinical trial material manufacturing capabilities allows us to provide a full service offering to our clients as they move from pre-clinical drug development into the clinic,” said CEO and co-founder David Barnes, Ph.D.
“The life science talent in Michigan compelled us to stay and grow here,” said Velesco Chief Operating Officer and co-founder Gerry Cox. “There’s a uniquely high concentration of the experienced pharmaceutical researchers Velesco needs to be successful in its aggressive growth plans.”
In conjunction with this expansion, Velesco was awarded a state High Tech Mega tax credit by the Michigan Economic Growth Authority. This credit will enhance Velesco’s operational capabilities.
About Velesco Pharmaceutical Services
Velesco Pharmaceutical Services was formed in 2007 by former Pfizer Michigan R&D colleagues and focuses on supporting the early stage work of pharmaceutical companies. Velesco’s founders, analytical chemists and drug formulation experts are pharmaceutical industry veterans with a track record of moving compounds through this significant phase of the drug development process. Velesco works with state of the art equipment in a high-quality (former Pfizer) facility. Velesco delivers on time high quality products and services, assistance with the FDA registration process and insightful consultation. More information about Velesco can be found at
www.velescopharma.com
.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.
